Intranasal delivery of dihydroergotamine by precision olfactory device
US11185497B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 2, 2020 |
| Grant date | Nov 30, 2021 |
| Priority date | — |
| Expiry date | Oct 2, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61M2205/8225
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (Cmax) of at least 750 pg/ml, (b) with a mean time to Cmax (Tmax) of DHE of less than 45 minutes, and (c) a mean plasma AUC0-inf of DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.